Immunic, Inc

1200 Avenue of the Americas, Suite 200
New York, NY 10036, USA

Phone: +49 89 2080 477 00

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing, Germany

Phone: +49 89 2080 477 00

Jan Van den Bossche

Jan Van den Bossche joined Immunic’s board in 2017. He is a Partner at Fund+, a healthcare-focused venture capital firm. Before joining Fund+, Mr. Van den Bossche served on the investor relations team at the Dutch life sciences and materials sciences company DSM, Geleen, The Netherlands, from 2013 to 2015. Previously, he worked for more than 12 years as a biotech analyst at Petercam, where he was involved in several public and private transactions of Belgian and Dutch biotech companies, including ThromoboGenics, Tigenix, UCB, AMT (Uniqure), IBA, and MDxHealth.
Mr. Van den Bossche holds a Bachelor of Economics and a master’s degree in Business Economics from the KU Leuven, Belgium. He also completed the CFA (Chartered Financial Analyst) program at the CFA Institute.
He serves on the Audit Committee and the Nominating and Corporate Governance Committee of Immunic’s board.